SCHEDULE: T. Rowe Price Discloses 10.7% Stake in Kymera Therapeutics

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.7% of Kymera Therapeutics' common stock as of August 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Kymera Therapeutics Inc. common stock.
• As of August 31, 2026, T. Rowe Price Associates, Inc. beneficially owns 8,873,588 shares of common stock.
• This represents 10.7% of the class of securities.
• The filing indicates sole voting power over 8,821,580 shares and sole dispositive power over 8,873,588 shares.
• T. Rowe Price Associates, Inc. is an investment adviser and is filing this statement in accordance with Rule 240.13d-1(b).
• The filing explicitly states that this is not an admission of beneficial ownership and that such ownership is expressly denied.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not dominant ownership stake by a major institutional investor, indicating confidence without aggressive control.

Positives

• Significant institutional ownership by a reputable investment firm (T. Rowe Price Associates, Inc.) can signal confidence in the company's long-term prospects.
• The ownership stake of 10.7% indicates a substantial investment, suggesting belief in Kymera Therapeutics' business model and potential growth.
• The filing is an amendment to a Schedule 13G, which is typically used by passive investors, suggesting T. Rowe Price is not seeking to control the company.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• The explicit denial of beneficial ownership by T. Rowe Price Associates, Inc. might suggest a nuanced relationship with the shares, potentially for client accounts rather than direct firm investment strategy.

Risks

• While T. Rowe Price is a significant holder, the filing does not detail specific risks related to Kymera Therapeutics' operations or market position.
• The denial of beneficial ownership could imply that the shares are held on behalf of various clients, meaning the investment strategy could change if client mandates shift.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Kymera Therapeutics. It solely reports the ownership stake of T. Rowe Price Associates, Inc.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that significant institutional investment, as reported in this Schedule 13G filing, is a common indicator of investor confidence in the biotechnology sector, particularly for companies like Kymera Therapeutics focused on novel drug development.

Comparison to Industry Standards

• As a Schedule 13G filing, it indicates a passive investment approach, which is standard for large asset managers like T. Rowe Price when holding shares on behalf of diversified client portfolios.
• The 10.7% stake is a substantial holding for a passive investor, placing T. Rowe Price among the significant institutional shareholders of Kymera Therapeutics.

Stakeholder Impact

• Shareholders: The increased visibility of a major institutional investor may attract further interest and potentially influence share price, though the passive nature of the holding suggests no immediate change in control.
• Management: The significant stake held by T. Rowe Price may provide a stable base of support, but also implies scrutiny from a major investor.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• T. Rowe Price Associates, Inc. will continue to monitor its investment in Kymera Therapeutics and may adjust its holdings based on market conditions and client mandates.
• Kymera Therapeutics will continue its operations and strategic initiatives, with the ownership structure now publicly updated.

Key Dates

Keywords

Kymera Therapeutics, T. Rowe Price Associates, Schedule 13G, Institutional Ownership, Common Stock, Investment Adviser, Beneficial Ownership